Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Climacteric. 2021 Feb 22;24(4):350–358. doi: 10.1080/13697137.2021.1882418

Table 3.

Factors addressed or not addressed in randomized clinical trials and observational studies.

Study variable Randomized clinical trials15,17,30,58,70 Observational studies3,7,9
MHT initiation at perimenopause No Yes
Status of symptoms at the time of MHT use No symptoms/exclusion of women with severe symptoms Yes
Duration of MHT Duration for intervention treatment that varied across clinical trials Personalized by clinicians
Type of MHT Single type of therapy that varied across clinical trials Personalized by clinicians
APOE genotype Randomized treatment arms not based on APOE genotype Requires further investigation
Adjustment of differences in medical comorbidity history among participants Controlled through exclusion health exclusion criteria Varied across studies

APOE, apolipoprotein E; MHT, menopausal hormone therapy.